Yang Wei-Hong, Bloch Donald B
Center for Immunology and Inflammatory Diseases of the General Medical Services, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA.
RNA. 2007 May;13(5):704-12. doi: 10.1261/rna.411907. Epub 2007 Mar 5.
Messenger RNA processing bodies (P-bodies) are cellular structures that have a direct role in mRNA degradation. P-bodies have also been implicated in RNAi-mediated post-transcriptional gene silencing. Despite the important roles of P-bodies in cellular biology, the constituents of P-bodies and their organization have been only partially defined. Approximately 5% of patients with the autoimmune disease primary biliary cirrhosis have antibodies directed against these structures. Recent advances in protein macroarray technology permit the simultaneous screening of thousands of proteins for reactivity with autoantibodies. We used serum from patients with anti-P-body autoantibodies to screen a protein macroarray and identified 67 potential autoantigens. Immunoreactive proteins included four known P-body components and three additional primary biliary cirrhosis autoantigens. Y-box protein 1 (YB-1), a 50-kDa RNA-binding protein that was not previously known to be a P-body component, was recognized by serum from four of seven patients. YB-1 colocalized with P-body components DCP1a and Ge-1. In cells subjected to arsenite-induced oxidative stress, YB-1 localized to TIA-containing stress granules. Both YB-1 and the previously identified P-body component RAP55 translocated from P-bodies to stress granules during oxidative stress. During recovery, however, the reappearance of YB-1 in P-bodies was delayed compared with that of RAP55, suggesting that YB-1 and RAP55 may have different functions. This study demonstrates that the combination of human autoantibodies and protein macroarray technology provides a novel method for identifying and characterizing components of mRNA P-bodies.
信使核糖核酸加工小体(P小体)是在信使核糖核酸降解中起直接作用的细胞结构。P小体也与RNA干扰介导的转录后基因沉默有关。尽管P小体在细胞生物学中具有重要作用,但其组成成分及其组织结构仅得到部分界定。约5%的自身免疫性疾病原发性胆汁性肝硬化患者体内存在针对这些结构的抗体。蛋白质芯片技术的最新进展使得能够同时筛选数千种蛋白质与自身抗体的反应性。我们使用抗P小体自身抗体患者的血清筛选蛋白质芯片,并鉴定出67种潜在自身抗原。免疫反应性蛋白质包括四种已知的P小体成分和另外三种原发性胆汁性肝硬化自身抗原。Y盒蛋白1(YB-1)是一种50 kDa的RNA结合蛋白,此前未知其为P小体成分,七名患者中有四名患者的血清识别出了该蛋白。YB-1与P小体成分DCP1a和Ge-1共定位。在受到亚砷酸盐诱导的氧化应激的细胞中,YB-1定位于含TIA的应激颗粒。在氧化应激期间,YB-1和先前鉴定的P小体成分RAP55都从P小体转移到应激颗粒。然而,在恢复过程中,与RAP55相比,YB-1在P小体中的重新出现延迟,这表明YB-1和RAP55可能具有不同功能。这项研究表明,人类自身抗体和蛋白质芯片技术的结合为鉴定和表征信使核糖核酸P小体的成分提供了一种新方法。